 RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics NASDAQ: CRSP sickle cell disease SCDbeta-thalassemia BT capped by preconditioning and has little conviction in BCMACD70 data within weeks. The analysts . 